Recommendations indicate a need for change in some widespread practices.
Sponsoring Organization: American Academy of DermatologyTarget Population: Primary care providers, dermatologists
Background and Objective
Most atopic dermatitis (AD) can be managed with topical therapies. However, in some patients with moderate or severe disease and in those on whom the disease has a significant physical, emotional, or social impact, phototherapy or systemic medication may be necessary.
Key Points
Phototherapy
The following forms of phototherapy have been found effective when aggressive topical therapy does not provide adequate control:
Systemic Therapy
This is indicated for adults and children with no response …
Reviewing Author
DisclosuresConsultant / Advisory board Astellas Pharmaceuticals
EquityVaxin
Grant / Research support NIH; NIH/NCI; Veteran’s Administration; Ferndale Laboratories; Kyowa Hakko Kirin Pharma, Inc.
Editorial boards Cancer Prevention Research; Photodermatology, Photoimmunology, & Photomedicine; UpToDate; eMedicine; Journal of Dermatological Sciences; JAMA Dermatology
Leadership positions in professional societies American Academy of Dermatology (Vice Chair, Committee on Science and Research); Photomedicine Society (Board of Directors)
DisclosuresConsultant / Advisory board Astellas Pharmaceuticals
EquityVaxin
Grant / Research support NIH; NIH/NCI; Veteran’s Administration; Ferndale Laboratories; Kyowa Hakko Kirin Pharma, Inc.
Editorial boards Cancer Prevention Research; Photodermatology, Photoimmunology, & Photomedicine; UpToDate; eMedicine; Journal of Dermatological Sciences; JAMA Dermatology
Leadership positions in professional societies American Academy of Dermatology (Vice Chair, Committee on Science and Research); Photomedicine Society (Board of Directors)